Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The brand has added a range of exciting new products especially formulated for oily skin.
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Recall does not include any metabolic deficiency nutrition formulas
ArisGlobal's industry-leading regulatory software chosen by top pharmaceutical company for IDMP preparation and global readiness
Agilent will integrate the technology into its lab informatics platforms, enabling customers to automate GC/MS data analysis
With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
Subscribe To Our Newsletter & Stay Updated